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INTRODUCTION 
Beta-thalassemias are a group of hereditary blood disorders 
characterized by absence or reduction in the synthesis of the beta chains of 
hemoglobin. The resultant  phenotypes varies grossly  ranging from 
clinically asymptomatic individuals  to those with severe anemia.  
Throughout the world the annual incidence estimated is around 1 in 100,000 
for symptomatic beta thalassemics.   
The average life expectancy of transfusion dependent  beta thalassemics 
have increased to third and the fourth decades over the past ten years. 
Moreover the quality of these transfusion dependent children have been 
transformed due to better health care facilities. Nevertheless,  the several  
complications of the disease have been disclosed as there is prolongation of 
life the complications may be partly due to the underlying disorder and is  
partly related to the conventional treatment with blood transfusions and 
subsequent  iron overload. Moreover, in contest to the multiorgan disease, 
aging related complications have been emerging   that adds up to the burden 
of the disease. These complications have to be care has to be dealt carefully 
for a proper management of the disease and its consequences. This masterly 
task demands dedicated work   by a team of hematologists or clinicians who 
 
 
have specific knowledge of thalassemias,  different specialists and well 
trained nurses.  The way in which the patients have been managed since 
childhood particularly with respect to their steady state hemoglobin levels 
and effectiveness of chelation therapy have major impact on outcome of the 
disease in relation to the frequency and severity of many complications.  
 In some of the developing countries individuals with thalassemia major 
are either untreated or transfused inadequately. Persistent severe anemia 
leads on to various consequences in these patients. The common findings in 
such underprivileged children  include growth retardation, pallor, jaundice, 
poor musculature, hepatosplenomegaly, leg ulcers, and development of 
masses from extramedullary hematopoiesis, and skeletal changes that result 
from expansion of the bone marrow.  
 On the other hand, complications due to iron overload contribute to the 
major issues in those patients receiving regular transfusion. The iron 
overload leads to serious complications including endocrine complication 
(growth retardation, , diabetes mellitus, and insufficiency of the parathyroid, 
thyroid, pituitary, failure of sexual maturation and less commonly, adrenal 
glands), dilated myocardiopathy, liver fibrosis and cirrhosis.  
 
 
Long term packed cell transfusion therapy leads on to iron overload 
which is almost an inevitable and deadly complication. Iron overload can 
lead on to early death mainly from excess iron induced cardiac disease. This 
has to to be prevented by prompt and adequate treatment with removal of 
excess iron from the body i.e iron chelation. Quality of life of these patients 
as measured by the complication free survival can be extended by optimal 
chelation therapy, which has been proved beyond doubts in various studies 
throughout the world.the pst two decades have been filled with vast medical 
advnces in the treatment of thalassemia major including  advances in 
transfusion regimes, better  iron chelation measures ,and  dramatic bone 
marrow transplantation. More than 200 mutations in β globin genes have 
been identified to cause the disease. The observed clinical heterogeneity in 
development of β thalassemia led to the identification of more than 200 
mutations so far. The clinical spectrum displayed by the thalassemic 
individuals is dominantly influenced by the type of mutation inherited 
Delineation of the genetic repertoire for beta thalassemic mutation is pre-
requisite for genetic counseling. These advances have definitely improved 
the prognosis for individuals with beta-thalassemia remarkably. 
  
 
 
MATERIALS AND METHODS 
Aim of the study : 
• To study the clinical profile of β thalassemia major children on repeated 
packed cell transfusion – registered in pediatric hematology OP , 
Institute Of Child Health And Research Centre, Madurai.  
• To identify the beta thalassemic traits among the family members of 
thalassemic children. 
• To determine the distribution of beta thalassemic major mutations 
among thalassemic patients and family members attending Pediatric 
Hematology Unit, Govt Rajaji Hospital, Madurai. 
Inclusion criteria: 
 Known beta thalassemic children aged between 6 months to 12 years 
who are registered in pediatric hematology op , Institute Of Child Health 
And Research Centre, Govt. Rajaji Hospital, Madurai and on repeated 
blood transfusion were recruited for study 
 
 
 
 
Exclusion criteria: 
 Children with other hemoglobinopathies such as hemoglobin J variant 
etc were excluded from the study. 
Methods: 
 Children fulfilling the criteria are included in the study. 
  Written consent obtained from the parents. 
 Medical history taken with specific emphasis to family and treatment 
history  
 Previous medical records were retrieved and analyzed 
 Complete clinical examination was done 
 Blood samples were collected for relevant investigations including blood 
grouping & typing, complete hemogram, iron studies, hemoglobin 
electrophoresis, blood sugar, bl.urea, s.creatinine, liver function tests, 
s.calcium, thyroid profile, viral markers for hepatitis, ELIZA for HIV. 
 Oral glucose tolerance test, ultrasound thyroid were done when 
indicated. 
 Radiological investigations including x rays of skull and chest, 
ultrasound abdomen, electrocardiogram, echocardiogram were done. 
 
 
 All findings are recorded in well structured  proforma. 
  Molecular analysis of   42 individuals comprising of 16 patients (aged 6 
months to 12 years) & 26 family members of 14 families were recruited 
for molecular analysis. 
 Complete blood count and molecular analysis of mutation IVS1-5 G to 
C, Cd41/42 were performed as multiplex PCR at Dept of Immunology, 
Madurai Kamaraj University. 
 Approximately, 3-5ml of peripheral blood (with EDTA, final 
concentration of 2.0 mg/ml) was collected, 0.5 ml of blood was utilized 
for performing complete blood count and remaining blood volume were 
transported to Dept of Immunology, Madurai Kamaraj University by 
maintaining the cold chain. Human genomic DNA was isolated from the 
blood samples by simple salting out procedure. 
 Molecular Genotyping 
 The β thalassemic mutation IVS1-5 G to C, Cd41/42 (-TCTT) were 
performed as multiplex PCR with internal control growth hormone. The 
allele specific mutation was performed individually with internal control 
primer and multiplex was optimized with minor modifications. The 
allele specific amplification was performed in 10μl reaction with 2μl of 
 
 
25ng/μl DNA as template and final concentration of 1X Roche PCR 
buffer, 1.5 mM MgCl2, 0.4μM of allele specific primers, 0.04 μM of 
internal control primers, 0.4U/μl of Taq polymerase and 0.01% gelatine 
as PCR additive and amplification was performed in Agilent PCR 
Machine. 2.0% of agarose gel prepared with 1X TBE, 3μl of 1X Xylene 
cyanol FF added to 10 μl of PCR product. The allele specific amplicons 
IVS1-5 (285bp), Cd41/42 (500bp), internal control (1065bp) were 
electrophoresed for 25 mins at 100V. The amplicon was viewed after 
running the gel at 100 volts and it has been documented in Gel doc          
(BioRad Pvt Ltd). 
Design of study: Prospective analytical study. 
Period of Study: November 2010 – January 2012 
Analysis: Statistical Analysis using SPSS package 17 
Collaborating Departments: Departments of Pediatrics, Pathology, 
Biochemistry, Cardiology, Endocrinology, and Radiology, Government  Rajaji 
Hospital, Madurai and Department of Immunology, Madurai Kamaraj 
University, Madurai . 
Ethical Clearance: obtained  
 
 
REVIEW OF LITERATURE 
HISTORICAL BACKGROUND: 
 β thalassemia is a monogenic hematological disorder first discovered by 
Thomas Cooley and Pear Lee in 1925 
1
 (Cooley & Lee, 1925), later 
termed as Cooley’anemia or Mediterranean anemia. 
 Whipple and Bradford 2,  described the pathology of the condition and 
were first used  to use the term ‘thalassaemia’ in their classical paper in 
1932.  The word thalassemia is derived  from the Greek word ‘qalassa’, 
which means ‘the sea’. 
  The first description of clinical features of various types of thalassemias 
were published during the  period between 1925 and 1940  
  The clearer picture about the inheritance of the condition is obtained by 
by amalgamation of the information from Europe and united states from 
1940 to 1960  
 The pattern of genetic inheritance of thalassemia was first described 
during the period of 1940–1950 
 Valentine and Neel3 (1944, 1948) classifies cooley’s anemia based on 
the severity of the disease naming the milder forms as thalassemia minor 
 
 
and severe types s thalassemia major. They have done pioneer work on 
the genetic transmission of thalassaemia , 
  In 1946 Vecchio4 noticed that the haemoglobin of Cooley’s anemia 
patients  was found to be more alkali-resistant than normal adult 
haemoglobin. Thereby he suggested that the amount of fetal hemoglobin 
is more in patients with cooley’s anemia than what is usually present 
after first year of life. 
 The microcytic anemia of cooley’s disease is often accompanied by the 
presence of large, pale macrocytes and target cells . Dameshek 
5
 pointed 
out this phenomenon and  called the condition ‘target-cell anaemia’ or 
‘leptocytosis’. 
 In 1952 Rich 6 suggested that thalassemia results due a defect in HbA 
synthesis with persistent production of HbF . 
 The important theoretical model for the genetic basis of thalassemia was 
set out by Ingram and Stretton
7
  in 1952.  
 The reasonably clearer picture of genetic control of thalassemia was 
obtained by 1960–1980. 
 
 
  Kan and Nathan8 in 1970 described a patient with  mild form of β 
thalassaemia intermedia whose both parents both had raised levels of 
HbA2. 
 The landmark in the treatment of thalassemia , Desferrioxamine , the 
iron cheltoe was introduced by Sephton-Smith
9,10
 in (1962, 1964).  
 The final unraveling of the molecular pathology of thalassemia was 
started in the year 1980 and thereafter.  
 
 
DISTRIBUTION: 
 
Most frequently, this disorder is found in the malarial, tropical and 
subtropical regions of Mediterranean countries, the Middle East, Central Asia, 
the Indian Subcontinent (South Asia) and Southeast Asia 
11
.  
 
India is a vast and diverse country with a population of over a billion 
with considerable genetic diversity. Approximately 26 million infants are born 
in India each year  which is  almost 20% of the total  world's infants. There 
have been several invasions from the Middle East, Central Asia and the West 
as well as commercial interactions through trade routes with  people of Central, 
Western and South East Asia, the Mediterranean region and Western Europe 
over thousands of years of its history resulting in a remarkable racial and 
cultural mix as well as considerable genetic diversity.  
 
 
The first case of thalassemia, described in a non-Mediterranean person, 
was from India. Subsequently, cases of thalassemia were documented in all 
parts of India. Every year 10,000 children with thalassemia major are born  in 
India,  which constitutes to  about 10% of the total number born in the world 
each year. 
Centers for care of thalassemia were started in the mid-1970s in 
Mumbai, Delhi and in other cities later. The International thalassemic 
federation and Indian Red Cross Society plays a  crucial role in arranging 
voluntary donations of blood and helped in improving the care of thalassemics. 
More emphasis on thalassemia care is also taken by Government of India in the 
12th 5-year Plan. Many states provide blood transfusion and chelation therapy 
free of cost. Further, bone marrow transplantation and cord blood stem cell 
storage facilities are available in a number of centres which improves the 
health care of these patients.  
 
 
 
 
 
 
 
 
BIOLOGY OF β THALASSEMIA: 
 
The β -globin gene is a small gene of 1.6 kb that occurs as a single copy 
in the haploid genome. It is arranged together with the other β -like globin 
genes (ε, Gγ, Aγ, and δ) in an ~60 kb long gene complex on the short arm of 
chromosome 11 (11p15) (Lin et al., 1985)
9
. Each gene is a separate 
transcriptional unit consisting of upstream regulatory sequences and the coding 
sequence (always split by two introns), followed by transcriptional termination 
signals that are probably important for RNA processing, mRNA stability, and 
efficient protein synthesis. Besides these local regulatory elements there is a 
region 6-18 kbp upstream from the β -globin gene that controls the expression 
of the entire β -globin gene complex during development and has been termed 
β –globin locus control region (β –LCR) 
 
 
 
 
 
Normal adults have a major hemoglobin called HbA, comprising about 
97% of the total, and a minor component,HbA2 which accounts for 2–3%. The 
main haemoglobin in fetal life is HbF, traces of which are found in normal 
adults. There are three embryonic haemoglobins, Hbs Gower 1 and 2. There is 
a series of physiological adaptations according to the differing oxygen 
requirements at various stages of development which is reflected by the 
production of these different hemoglobins. In addition, there are some minor 
haemoglobin components that are the result of postsynthetic modifications that 
may take place in vivo, or in vitro during storage in the laboratory. All the 
normal human haemoglobins are tetramers of two pairs of unlike globin chains. 
Adult and fetal haemoglobins have a chains associated with β(HbA, α 2β2), δ 
(HbA2,α2δ2) or γ chains (HbF, α2γ2), whereas in the embryo δ chains combine 
 
 
with γ (Hb Portland, δ2,γ2) or ε chains (Hb Gower 1, δ2,ε2), and α and ε chains 
combine to form Hb Gower 2 (α2ε2). 
 
Developmental changes in hemoglobin production: 
 Human haemoglobin is heterogeneous at all stages of development, 
beginning with the youngest embryos and continuing throughout adult life. In 
embryos, haemoglobin synthesis is confined to the yolk sac, where Hbs Gower 
1 (δ2e 2), Gower 2 (α2ε2) and Portland (δ2γ2) are produced. Synthesis of β 
chain becomes detectable at about 6 weeks. At around 7–8 weeks’ gestation the 
liver becomes the major site of erythropoiesis, producing large enucleated red 
cells. Throughout most of fetal life HbF production predominates, with a small 
 
 
amount (<10%) of HbA. At mid-term the bone marrow begins to take over as 
the major site of red-cell production, though erythropoiesis is also found in the 
spleen, as well as in other tissues. Towards the end of gestation there is a 
gradual and reciprocal switch from HbF to A production. At birth, the cord 
blood normally contains ~70% HbF and this declines to ~20% by 3 months, 
7.5% at 6 months, and less than 2% by the age of 1 year. Both fetal and adult 
haemoglobins are produced in the same cell during the switching period, with a 
gradual increase in the proportion of cells containing predominantly HbA. The 
proportion of HbF continues to decline throughout childhood and probably 
throughout adult life. 
 
 
 
The β thalassaemias 
 The basic defect in beta thalassemia  is a reduction in the β globin chain 
production. On the other hand, α globin chins are produced in excess  leading 
to imbalance in the production of globin synthesis. In all severe forms of beta 
thalassemia there is persistence of HbF synthesis  beyond birth and infancy but 
in variable degrees. Yet overall HbF synthesis and output is essentially 
 
 
inadequate to compensate for the marked deficiency of HbA.  In other words 
there is never a match between the production of α chains to that of output of β 
and γ chains chains in beta thalassemia. Thus the hallmark of this disease is the 
unbalanced  production globin chains  and an excess of α chains is therefore 
the pathogenic marker of β thalassaemia.  
Classically in thalassemia, there is defect  in the maturation of  erythroid 
precursors  along  with ineffective erythropoiesis and a shortened red cell 
survival as the  excessive unbound α chains precipitate within in the red-cell 
precursors in the marrow and in their progeny in the peripheral blood.   There is 
intense proliferative drive in the ineffective bone marrow by the resultant 
anaemia , which leads to its expansion. Thereby a variety of growth and 
metabolic abnormalities develop and also results in n array of skeletal 
deformities. There is shunting of blood through the vastly expanded marrow 
spaces and the consequent hemodilution leads to further exacerbation of the 
anemia. This is augmented by the entrapment of the abnormal red cells in the 
enlarged spleen. The characteristic increased iron absorption and the 
consequent iron loading occurs due to the hyperplasia of the bone marrow 
which is often exaggerated by the need for regular packed cell transfusion. 
There  is leads to progressive iron deposition in various tissues. If the excessive 
 
 
iron that gets deposited is not removed by any means, multi organ failure 
ensues that culminates to death of these patients. 
Mutations in beta thalassemia major 
More than 200 mutations in β globin genes have been identified to cause 
the disease. The observed clinical heterogeneity in development of β 
thalassemia led to the identification of more than 200 mutations so far. Most of 
these mutations cause defects in transcription, RNA splicing, RNA 
modification and translation because of frame shifts and nonsense codons or 
produce highly unstable β -globin products. However, vast majority of β -
thalassemia syndromes are caused by point mutations within the β –globin 
gene itself or in its immediate flanking sequences 
37
.  
 
 
 
 
 
 
 
 
 
 
Common types of beta thalassemic mutation : severity and ethnic types 
 
 
 
 
 
6 common Indian β-thalassemia mutations are [IVS1–5(G→C), CD 
41/42(−CTTT), CD 15(G→A), etc. Distribution of these mutations varies 
among different regions. The commonest mutation in south India is [IVS1–
5(G→C) amounting to 60%, and in Tamilnadu constituting to 56.5%. 
 
 
 
 
The clinical spectrum displayed by the thalassemic individuals is 
dominantly influenced by the type of mutation inherited. Hence, diverse forms 
of thalassemia arise in mutations that affect nearly every step in globin chain 
expression i.e transcription, translation, processing and so on. Reduced or 
absent beta globin synthesis prevents adequate hemoglobin accumulation so 
that the cells are hypochromic and microcytic. Assessment of red cell 
parameters is the foremost laboratory investigation in the diagnostic workup of 
β thalassaemias. Routine diagnostic modalities for identification of β 
thalassaemia include low red cell values (MCV, MCH, RDW) on complete 
blood picture (CP), altered erythrocyte morphology and increased Hb A2 levels 
on high performance liquid chromatography (HPLC) or Hb electrophoresis. 
Mentzer index (mentzer et al.,1973)
10
calculated MCV/RBC count < 13.5 
favors thalassemia over iron deficiency. In thalassemia, RBC production is 
preserved, so the RBC count is normal with a low MCV. 
 
 
 
 
 
The clinical manifestations of the disease are due to a variety of  pathological 
mechanisms. 
Pathology  Consequence  
primary mutation in genes coding 
globin chains 
Imbalance in the synthesis of globin 
chains synthesis 
Excess α chains that get precipitated 
in the red cell precursors and their 
progeny 
Ineffective erythropoiesis and anemia 
abnormal organ function Anaemia, splenomegaly, 
hepatomegaly, hypercoagulable state 
Severe anemia Induction of  erythropoietin 
production and marrow expansion 
with resultant skeletal deformity and 
metabolic abnormalities 
Adaptivity changes in cardiovascular 
function 
abnormal iron metabolism Iron overload which induces damage 
to liver, endocrine organs and 
myocardium 
Therapy induced Iron overload, , blood-borne infection, 
drug toxicity. 
 
 
 
 
Outline summary of pathophysiology of beta thalassemia 
 
 
 
 
 
 
Defective red-cell maturation and survival in β thalassaemia 
Ineffective erythropoiesis: 
 The anemia in beta thalassemia is due to both ineffective erythropoiesis 
as well as shortened survival of the red cells. The ineffective erythropoiesis 
contributes the maximum to anemia as there is a large scale destruction of the 
erythroid precursors in the bone marrow.  Ferrokinetic and erythrokinetic 
studies and concluded that the anemia is more predominantly due to ineffective 
erythropoiesis although the destruction of erythroblasts is also reflected in the 
pattern of bilirubin metabolism
12
.  
Haemolysis:  
There reduced survival of abnormal red cells contribute to anemia in 
thalassemia patients but is found to  less important than ineffective 
erythropoiesis in determining the severity of anemia. In various studies 
13,14,15,17,18,19
Using either the Ashby or 51Cr-labelling methods, survival time of 
the red cells of thalassemics  ranged from 7 to 22 days. Two other studies 
13,
 
20
 
concluded that there are two populations of red cells, one which is very rapidly 
destroyed. There is evidence, that the longer-lived cells are richer in HbF while 
the shortlived population contains mainly HbA or α-chain precipitates. The 
 
 
alterations in the membrane deformabilty , stability and the cellular 
dehydration of the red cells are probably because of the accumulation of the 
excess α chains  at the membrane and its skeleton21, 22. The changes in the 
membrane characterized by a reduced spectrin/band 3 ratio, and partial 
oxidation and defective function of band 4.1 are associated with these 
abnormalities
23
. 
Secondary effects of ineffective erythropoiesis and anaemia: 
Response to anaemia 
The profound anemia induces increased production of erythropoietin in 
response to the chronic hypoxia. In  pioneer study 
24
  found that there are 
significantly elevated  Erythropoietin levels  in the blood and  as well as urine 
of patients with haemoglobin values of 7.0 g/dl or less. 
Erythroid expansion 
In beta thalassemia there is ineffective erythropoiesis and associated  
expansion of the ineffective erythroid mass that is  estimated to range between 
10 and 30 times normal in some cases 
25, 26
 . This uncontrolled expansion of the 
erythroid mass is of profound importance in the generation of most distressing 
clinical features of the disease, particularly bone deformities and, occasionally, 
 
 
the production of extramedullary tumour masses. In young children, it also 
imposes an excessive metabolic burden. As a consequence these children fail to 
grow, poor muscular development, and reduced body fat and weight . There is 
exacerbation of the anemia undoubtedly due to shunting of blood through the 
massively expanded marrow  together with splenomegaly
27
 . There is high 
output state in profoundly anemic thalassemic children due to anemia and 
associated hypervolaemia that  combine to produce cardiomegaly. There is 
elevated level of urates in urine and serum uric acid levels when compared to 
control subjects is evident  as there is increased  destruction of red-cell 
precursors. 
Splenomegaly and hypersplenism 
Mechanisms 
One of the functions of the spleen is to act as a filter, retaining defective 
blood cells and foreign particles in a bed of phagocytes
28
 . Approximately 5–
10% of splenic blood is diverted into the red pulp and slowly percolates 
through a non-endothelialized mesh containing macrophages, after which it 
reenters the circulation through narrow slits, measuring 1–3 μm, in the 
endothelial sinuses. Sometimes called ‘work hypertrophy’, a term which at 
least hides our total ignorance of the mechanisms involved,the exposure of the 
 
 
reticuloendothelial elements of the spleen to abnormal red cells like those of β 
thalassaemics leads to its progressive enlargement. This concept is supported 
by the observation that children who have received regular blood transfusions 
from early in life, and hence who do not have many abnormal red cells in their 
circulation, do not develop significant splenomegaly. The early observations in 
1963 showed that blood cells carrying inclusions only appear in the peripheral 
blood after splenectomy also pointed to the central importance of the spleen in 
the pathophysiology of the anaemia
29
. Extramedullary haemopoiesis may also 
contribute to splenomegaly, and hepatomegaly. 
Consequence of splenomegaly 
Splenomegly leads to entrapment of all the formed elements of the blood 
, producing anaemia, thrombocytopenia and neutropenia. The anaemia in beta 
thalassemia  has a complicated basis,  which includes ineffective erythropoiesis 
with shortening of the red-cell survival, a dilutional element caused by pooling 
of a proportion of the red-cell mass in the spleen, and the ill-understood effect 
of increasing the plasma volume. 
In the study  9 to 40% of the total red-cell mass  were found to be 
entrapped in the splenic pool
18
 . In severe forms of beta thalassemia  spleen is 
also the site of extensive extramedullary haematopoiesis .Interestingly, Blendis 
 
 
18
 et al. (1974) noted that splenectomy may be associated with a growth spurt, 
suggesting that an enlarged spleen might have a deleterious effect on 
development. 
Plasma volume expansion 
Plasma volume expansion worsens the anemia and also poses  a greater 
load on the myocardium. The plasma volume doesnot return normal after 
splenectomy suggesting that the plasma volume expansion is not entirely due 
to splenomegaly
18
. It has been suggested that  vascular shunt mechanism across 
the vastly expanded bone marrow results in plasma volume expansion, As in 
other diseases which result in expansion of plasma volume. 
Iron overload 
One of the most well recognized and age old complication of 
thalassemia is  generalized iron overload and deposition iron in tissues and 
organs
2,16,30,31,32
  Both the erratic absorption of iron from the gut as well as from 
transfusion delivers excess iron into the body system. The patients who are 
either  inadequately transfused and those with intermediate forms of 
thalassemia, increased absorption from the gut is considered to be the 
predominant mechanism of iron over load. On the other hand, in patients who 
 
 
are adequately transfused children the latter mechanism predominates as the 
major route of iron overload. 
Mechanisms and rate of iron loading 
The amount of iron in the body stores and the level of erythropoietic 
activity  are the two major factors that influence the rate of absorption of iron 
from the intestine. A unit of blood contains approximately 200 mg of iron and, 
since there is no  natural way by which iron can be excreted   from the body,  a 
regular transfusion regimen rapidly increases the body iron stores.  
Additionally  iron absorption  from the gut increases dramatically in the 
presence of ineffective erythropoiesis and erythroid expansion; the drive to 
increased iron absorption overcomes the physiological mechanisms whereby it 
is normally reduced in the presence of increased body stores. 
Although being life saving in these patients, red cell transfusions  are 
responsible for series of complications and thereby exposes the patient to  a 
variety of risks. Among  all the complications  of regular red cell transfusion 
therapy iron overload is the most relevant  complication. 
 
 
 
 
Mechanisms of tissue damage in iron loading  
Although  iron is vital for  living processes, excess iron can generate 
extremely toxic free radicals, which cause widespread tissue damage under 
certain conditions. Normally iron  is tightly bound to storage or transport 
proteins;  for example catalytic effect of iron in free radical production can be 
prevented by binding of plasma iron to transferrin. 
33
. However,when the 
transferring gets saturated with the increasing levels of iron overload, non 
transferrin bound plasma iron (NTPI) becomes detectble in the blood which is 
potentially toxic to body
34,35,36
.  Moreover , the low molecular mass iron that is 
present in the serum of patients with iron overload  is also present in many 
other tissues
32
. Generally  iron is usually tightly associated with haem and non-
haem proteins such as ferritin, transferrin and haemoglobin, but on imposing an 
oxidant stress on iron-containing proteins can release some ‘free’ iron. The 
most important pathological consequences of iron overload  result  from 
involvement of the liver, heart and endocrine glands despite the fact that iron 
gets deposited  
Clinical consequences of iron overload: 
Iron overload is attributes to most of the complications  of the 
disease.heart, liver and various endocrine glands are the most commonly 
 
 
affected organs. The commonly affected endocrine glands include pituitary 
gland, thyroid gland, parathyroid gland, pancreas, gonads. Clinically they may 
not be evident initially and hence investigations are required for early detection 
and should be done in all thalassemia children from time to time and treat them 
appropriately. Diabetes may be seen as early as five years of age. Dysfunction 
of thyroid and parathyroid gland may be subclinical initially, so blood sugar 
estimation, thyroid function assessment, s. calcium  should be done frequently. 
Liver is affected by due to various causes including repeated blood borne 
infections and excessive iron deposition. Hence it is essential to do liver 
function tests and viral markers frequently atleast once in 6 months.it is also 
important to monitor the organ functions regularly particularly such as heart, 
endocrine glands, growth failure and complications due repeated infections. 
Growth failure is seen in nearly 30 % of western children and and nearly all 
children in our country.  The mean age of attainment of sexual maturity is also 
delayed. Various cause have been attributed to growth retardation include poor 
compliance to regular blood transfusion, inadequate chelation, growth hormone 
deficiency secondary to  pituitary hemosiderosis, defective hepatic biosynthesis 
of of somatomedins and sex hormone deficiency and chronic hypoxia 
secondary to anemia. Treatment of subclinical hypothyroidism is debatable. 
Close monitoring of the patients is necessary when treatment is considered as 
 
 
unnecessary. In overt hypothyroidism characterized by low T4 levels with 
signs and symptoms such as mental and physical letharginess, cold intolerance, 
weight gain, constipation etc, treatment with L- thyroxine is considered. 
Abnormal thyroid function may be reversible t the early stage through 
intensive chelation therapy.  
 Cardiac complications leads to 70% of deaths in beta thalassemia, which 
include cardiac failure and arrhymias. Excess iron gets deposited in the heart 
especially in ventricular walls and the conduction system. When iron 
accumulates in the cardiac tissue, free iron damages the cells sue to lipid 
peroxidation and lysosomal rupture. Cardiac complication in thalassemic 
children include overt cardiomyopathy, dilatation of  the left atrium, dilatation 
of the aortic root dilatation , reduction in the internal dimension of left ventricle 
both in systole and diastole.   Early detection of cardiac involvement can be 
done by evaluation of ferritin levels and various tests to evaluate cardiac 
functions like ECG, echo etc. All these  tests can only  assist in evaluation of 
cardiac involvement , but donot quantitate cardiac evaluation.  The best 
available method to assess the severity of cardiac evaluation is T2 weighted 
cardiac MRI  but it is available only in certain centres now. 
 
 
 
Management of thalassemia major 
 Correction of anemia by packed cell transfusions 
 Removal of excess iron by chelation therapy 
 Management of complications 
 Curative treatment : stem cell transplantation 
 Future treatment: gene therapy 
 Prevention of the disease by  genetic counseling, prenatal diagnosis and 
preimplantation genetics 
Transfusion therapy 
The goals of treatment with transfusion  is to correct the anemia and to 
suppress ineffective erythropoiesis. Regular packed cell transfusion is presently 
the mainstay of treatment. 
Type of transfusion Pre transfusion Hb Mean Hb maintaineed 
Palliative  <7g% <8.5 g% 
Hyper transfusion  >10g% >12 g% 
Super transfusion  >12 g% >14 g% 
Moderate transfusion  9 -10.5 g% >12g% 
 
 
 
Current recommendation is to maintain the mean post transfusion Hemoglobin 
levels of 12g% and transfuse the child at the pretransfusion level of 9 to 10.5 
g%. (moderate transfusion). Post transfusion hemoglobin should not rise above 
15 -16 g%. 
Transfusion dependent complications 
Iron overload  
Infections  - Viral (HIV, HCV, HBV, 
HTLV1, west nile virus 
- Bacterial  
- Parasitic  
- Creutzfeld – Jacob disease 
- Emerging and new pathogens 
Haemolytic reactions -acute haemolytic rections 
- delayed haemolytic reactions. 
- autoimmune haemolytic anemia 
Non haemolytic reactions   - Allergic and anphylactic 
rections 
- Febrile non haemolytic reactions 
- Transfusion related acute lung 
injury 
- Transfusion associated graft 
versus host disease 
- Circulatory overload 
- Post transfusion purpura 
 
 
Chelation therapy: 
Iron overload is the main problem encountered in the management of 
thalassemia. .  As there  are no effective mechanisms for excretion of iron from 
the body , the use of iron chelators is the  the only way for the removal of 
excess iron . The use of iron chelators is mainly aimed at reducing the iron 
stores in the body and to maintain the iron store in the body at low levels.The 
drugs used presently include desferroxamine , Deferiprone, deferasirox. 
Desferrioxamine : The dose is 30 -40mg/kg/day givesubcutanuoesly over  8-
10 hours for 6 nights a week using subcutaneous desferal infusion pump. Depot 
desferrioxamine is a newer modification of chelation therapy. 
Deferiprone : The dose is 75 -100mg/kg/day in three to four divided doses 
orally. It  found to be 70 -100% as effective as desferrioxamine and leads to 
effective reduction in both serum ferritin and tissue iron overload. 
Deferasirox : Newer oral iron chelator for treatment of iron overload 
associated with chronic blood transfusion. The dose is 20 -40mg once daily 
adjusted upon patient’s response, serum ferritin and serum creatinine levels. It 
is found to be nearly five times as effective as subcutaneous desferrioxamine 
and ten times more potent than deferiprone in animal studies 
 
 
 As a general rule, chelation therapy should be started patients with thalassemia 
major once they had received ten to twenty transfusions or when serum ferritin 
levels rises above 1000µg/dl
55
. 
Prospective and retrospective studies have shown that myocardial sidereosis is 
reduced more effectively by deferiprone monotherapy and has reduced the 
cardiac morbidity and mortality
48,49,50
. 
Intensive therapy with iron chelators seems to bring about improvement in 
glucose tolerance, abnormal thyroid function and other ill effects of iron 
overload in early stages.
51,52,53
. 
Future perspectives: 
Newer drugs like PIH ( pyridoxal isonicotynoyl hydrozone) HBED- and 
dimethyl HBED though looked promising as they are relatively non toxic and 
effective, however they are non patentable. 
Pharmacological manipulation of HbF inducing drugs like hydroxyl 
urea, butyrates, 5-azacytidine
54
. Pharmacological gene manipulations heve 
been tried in order to increase the production of HbF and to prevent   the 
precipitation of unpaired Hb chains. 
 
 
 
Indications for splenectomy: 
 When the yearly requirement of packed cell transfusion  increases more 
than double the basal requirement. i.e. around 230 -250 cc per Kg. 
 Decreased platelet count – relatively late manifestation of 
hypersplenism. 
All patients needing splenectomy should receive  Pneumococcal vaccine , 
H. influenza type b vaccine and meningococcal vaccine about 6 to 8 weeks 
prior to splenectomy .  Splenectomy is  better avoided in  children  less than 5 
years of age. 
 
Stem cell transplantation: is the only curative treatment available at present 
with a ray of hope for permanent cure and better future for children with 
genetic disorders such as thalassemia. 
Prenatal diagnosis and genetic counseling: 
Prevention of beta thalassemia major is generally based on carrier 
detection, genetic counseling and prenatal diagnosis. Genetic counseling is 
usually given for individuals and at risk couples ( i.e. both carriers). 
Information  regarding the mode of inheritance , the genetic risk of having 
 
 
affected children  and the natural history of the disease including the  available 
treatment and therapies under investigation are provided. 
Prenatal diagnosis  is possible by the analysis of DNA extracted from the 
fetal cells obtained by amniocentesis or chorionic villi sampling for 
pregnancies at increased risk. Identification of  disease causing mutation  is a 
must be before prenatal testing is performed. Currently  analysis of fetal cells 
in the maternal blood and analysis of fetal DNA in maternal plasma for the 
presence of father’s mutation are  under investigation. Preimplantation genetic 
diagnosis can be offered to families in which the disease causing mutations 
have been identified. 
Pre implantation genetics 
A newer  genuine method  of prevention of disease would be pre 
implantation diagnosis by the polymerase chain reaction (PCR). In this method 
the isolation of 1-2 blastomeres from embryos or, alternatively, aspiration of a 
polar body from oocytes is performed .Ideally if the mutation causing the 
disease is excluded , the remaining blastomeres are transferred into the 
mother’s womb for normal fetal development 38. In future there is a expected  
possibility to provide a comprehensive genetic screening of embryos fertilized 
and developed in vitro and thereby reduction or  elimination of  beta 
 
 
thalassemia by the micromanipulation of the gamete and embryo biopsy 
combined with the sensitive PCR technology 
39
. 
Prevention of beta thalassemia 
  Only 10 to 15% thalassemic children born in India receive optimal 
treatment. The cost of treatment for thalassemic child is around Rs.1,00,000 
annually. Curative treatment in the form of bone marrow is not affordable by 
most of our patients. The birth of thalassemic child places considerable 
physical, economic and emotional strain not only to the child and the family 
but also to the nation.  So the emphasis must shift from treatment to prevention 
of such births. Prospective prevention which includes population education, 
mass screening, genetic counseling, and prenatal diagnosis and possibly 
preimplantation genetics, is the only effective way to cope successfully with 
such a disease. Various screening tests have been used to perform mass 
screening in population. These include menzter’s index, MCV, NESTROFT 
(Naked Eye Single Tube Red cell Osmotic fragility test) etc. However,  none 
can estimate the confirmatory HbA2 estimation for the definitive identification 
of beta thalassemia carriers. Those who are confirmed to have thalassemia trait 
should be counseled for testing their partner. If both are tested to be positive, 
they need to be counseled regarding prenatal diagnosis in first trimester with 
 
 
chorionic villi sampling and in the second trimester with amniocentesis. Thus 
every baby born to two carriers of thalassemia should be screened in utero and 
if those fetuses affected , termination should be advised.  
 
  
 
 
OBSERVATION AND ANALYSIS 
 
Total number of children included in the study: 32 
Sex and age distribution: 
 
AGE DISTRIBUTION 
Years Male Female Total 
1-5 Years 10 7 17 
5-8 Years 3 2 5 
8-14 Years 6 4 10 
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Sex No of patients  
MALE  19 
FEMALE  13 
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District wise distribution 
 Male Female Total 
Dindigul 1 1 2 
Madurai 12 7 19 
Theni 4 1 5 
Virudhunagar 1 2 3 
Ramnad 0 2 2 
Tirunelveli 1 0 1 
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Consanguinity 
Degree of 
consanguinity  
No of 
families  
2nd 5 
3rd 20 
ncm 7 
 
 
 
 
 
 
 
5
20
7
2nd
3rd
ncm
 
 
Family history: 
- None of the parents were  affected 
- 3 pairs of siblings affected. 
Transfusion details 
- All children were repeated packed cell transfusions 
- Average pre transfusion Hb  -5 -7 g% 
- Children received around 20 transfusions per year. 
- Average interval between the transfusion – 3 to 4 weeks 
Chelation details: 
- All beta thalassemic children  were on oral iron chelation therapy 
- Irregular compliance to the drug. 
Splenectomy : 
- 2 out of the 32 cases had undergone splenectomy  
Blood sugar: 
- Blood sugar elevated in 2 children out of 32 children 
- On glucose tolerance test – impaired glucose tolerance  
- Mean value – 99.75 mgs% & Standard deviation – 41.08. 
 
 
Blood urea and serum creatinine  
- Normal in all 32 children 
- Urea - 22.41±10.99 mg% 
- Creatinine - 0.82±0.82mg% 
Liver function tests: 
- S. bilirubin elevated in 3 out of 32 children 
- Mean value: 1.47 ±1.09 mg% 
- Indirect bilirubin elevated in 3 out of 32 children 
- Mean value : 0.88±1.05 
- SGOT elevated in 8 out of 32 children 
- Mean value: 53.97±42.07 IU/L 
- SGPT elevated in 19 children 
- Mean value: 88.99±137.93 
- Both  SGPT and SGOT elevated in 8 children. 
- S. total proteins decreased in  7 out of 32 children 
- Mean value: 6.63 ± 0.75 
- S. Albumin decreased in 19 out of 32 children 
- Mean value: 3.71±0.45 
- S. globulin mean value : 2.9±0.61 
 
 
BLOOD SUGAR LEVEL IN STUDY GROUP 
 
SERUM FERRITIN LEVELS IN STUDY GROUP 
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Endocrine abnormalities: 
- All children were short statured 
- 9 children (7 males & 2 females) had subclinical hypothyroidism 
(26.47%) .  
- S. Calcium normal in all children 
 
Mean values: 
- T3 - 1.29±0.23 
- T4 - 9.22±1.27 
- TSH - 2.76±1.99 
 
 
 
 
 
 
 
 
 
 1 to 6years  6 to 12 years  
No of children  16  18  
No. of hypothyroid  4 5  
% among all children  25% 27.77%  
% among hypothyroid  44.44% 55.56%  
Av. Ferritin level  3138.9 ng/dl 3016.96 ng/dl  
 
HYPOTHYROIDISM IN STUDY GROUP 
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CARDIAC EVALUVATION IN STUDY GROUP 
 
  
Cardiac evaluation 
- Normal study – 29 children 
- 1 - dilated coronary sinus & small OS ASD 
- 1- bicuspid aortic valve with fused raphe  
- 1- slightly dilated LV with MR grade I. 
Viral markers: 
- 2 children among the 32 patients positive for HBsAg. 
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ELISA for HIV 
- 2 children among the 32 patients positive for HIV 
• Beta thalassemic trait was confirmed by a combination of various 
diagnostic parameters that include MCV <75fL, normal RDW, 
Hct>30%, and mentzer index <13. 
All parents and 77% of  siblings were  found to be thalassemia traits in this 
study. 
HEMATOLOGICAL PARAMETERS IN STUDY GROUP 
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Beta thalassemic trait was confirmed by a combination of various 
diagnostic parameters. Individuals with MCV <75fL, normal RDW, Hct>30%, 
and mentzer index <13.5 identified as carrier or thalassemic trait. 
15 individuals had mentzer index <13.5, 26 individuals had MCV 
<75fL, 15 with normal RDW, 16 with Hct>30%.  We performed molecular 
genotyping of beta thalassemic major mutation (IVS1-5 G to C and Cd41/42(-
TCTT) in all patient and their family members. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Multiplex PCR results of  the study group 
 
PCR  amplification of IVS1-5 nt (G to C) and Cd41/42 (-TCTT) mutant 
allele in Beta thalassemic patients 
The first row lane1 is no template control, 2 DNA ladder, 3 to 23  
samples    
The second row: 1 positive control for mutants, 2 DNA ladder, 3 to 23 
samples, 24 negative control (healthy individual). 
 
 
 
Among the 42 samples, 16 were   confirmed as thalassemia major and 25 
individuals were thalassemia trait based on hematological parameters. 25 
individuals (8 patients, 17 family members) out of 42 possessed IVS1-5 (G to 
C) and none positive for the mutant Cd41/42. 
25 (8 patients, 17 individuals comprised of parents and siblings) of 42 
individuals possessed the major mutant   IVS1-5 (G to C) - 71% and was 
found to be statistically significant - p<0.05(Chi –Square test). None were 
positive for the mutant Cd41/42(-TCTT). Genetic status for the remaining 
samples could not be identified due to technical difficulties 
 
 
 
  
 
 
RELATIONSHIP BETWEEN THYROID PROFILE AND FERRITIN 
TABLE NO. 1 [A]  -  THYROID TEST 
Name of the Test Correlation 
between 
Correlation 
Value 
Significant 
Pearsons 
Correlation 
Ferritin and T3 -0.107 0.56 
Kendall's Tau_b Ferritin and T3 -0.084 0.51 
Spearman Ferritin and T3 -0.134 0.46 
    
TABLE NO. 1 [B]  -  THYROID TEST 
Name of the Test Correlation 
between 
Correlation 
Value 
Significant 
Pearsons 
Correlation 
Ferritin and T4 -0.118 0.12 
Kendall's Tau_b Ferritin and T4 -0.2 0.11 
Spearman Ferritin and T4 -0.292 0.104 
    
TABLE NO. 1 [C] -  THYROID TEST 
Name of the Test Correlation 
between 
Correlation 
Value 
Significant 
Pearsons 
Correlation 
Ferritin and 
TSH 
0.03 0.87 
Kendall's Tau_b Ferritin and 
TSH 
0.012 0.92 
Spearman Ferritin and -0.03 0.87 
 
 
TSH 
    
TABLE NO. 1 [D] -  THYROID TEST 
ANOVA F Ratio P Value Significant 
 101.75 O.OOO P < 0.05 
    
 
This table showed that Ferritin and T3 , Ferritin and T4 were negative 
correlated but TSH had positive correlation .  Ferritin had significant 
correlation  with T3,T4, TSH.  It was also proved by Kendall's Tau_b and 
Spearman rank correlation for Ferritin and T3  and Ferritin and T4 but Ferritin 
and TSH showed positive correlation by Kendall's Tau_b, and negative 
correlation by spearman method.  By analysis of variance showed significant 
effective changes of ferritin over T3,T4 and TSH.  F ratio value was 101.750 
which showed significant [P<0.05]. 
 
 
 
 
 
 
RELATIONSHIP BETWEEN FERRITIN AND LIVER FUNCTION TEST 
TABLE NO. 2 [A]  -  LIVER FUNCTION TEST 
Name of the 
Test 
Correlation 
between 
Correlation 
Value 
Significant 
Pearsons 
Correlation 
Ferritin and 
SGPT 
0.108 0.55 
Kendall's Tau_b Ferritin and 
SGPT 
0.135 0.28 
Spearman Ferritin and 
SGPT 
0.181 0.32 
    
TABLE NO. 2 [B]  -  LIVER FUNCTION TEST 
Name of the 
Test 
Correlation 
between 
Correlation 
Value 
Significant 
Pearsons 
Correlation 
Ferritin and 
SGOT 
0.273 0.13 
Kendall's Tau_b Ferritin and 
SGOT 
0.137 0.27 
Spearman Ferritin and 0.208 0.25 
 
 
SGOT 
    
TABLE NO. 2 [B]  -  LIVER FUNCTION TEST 
Name of the 
Test 
Correlation 
between 
Correlation 
Value 
Significant 
Pearsons 
Correlation 
Ferritin and ALP 0.14 0.44 
Kendall's Tau_b Ferritin and ALP 0.158 0.2 
Spearman Ferritin and ALP 0.217 0.233 
    
TABLE NO. 1 [D] -   LIVER FUNCTION TEST 
ANOVA F Ratio P Value Significant 
 95.699 O.OOO P < 0.05 
    
 
This table revealed that Ferritin had positively correlated with Liver Function 
test. By analysis of variance showed the F Ratio was significant [p<0.05] 
p=0.000 .   
Liver Function had significant correltion with Ferritin level.  Intra class single 
and average measures showed positive correlation [0.367]. 
 
 
RELATIONSHIP BETWEEN FERRITIN AND SERUM PROTEIN 
TABLE NO. 3 [A]  -  Protein total 
Name of the 
Test 
Correlation 
between 
Correlation 
Value 
Significant 
Pearsons 
Correlation 
Ferritin and 
Protein 
0.182 0.31 
Kendall's Tau_b Ferritin and 
Protein 
0.029 0.82 
Spearman Ferritin and 
Protein 
0.049 0.79 
TABLE NO. 3 [D] -   PROTEIN  
ANOVA F Ratio P Value Significant 
 101.035 O.OOO P < 0.05 
 
This table revealed that correlation between Ferritin and Protein  was positively 
correlated and it is evidenced by Kendall's Tau_b and spearman method .  By 
analysis of variance F ratio was 101.035 which was significant [p<0.05] 
Hence, Ferritin had more effective on Protein.  Intra class correlation 
coefficient for single and average measures showed positive correlation. 
 
 
 
RELATIONSHIP BETWEEN FERRITIN AND SERUM ALBUMIN  AND 
GLOBULIN 
 
TABLE NO. 4 [A]  -  ALBUMIN 
Name of the Test Correlation 
between 
Correlation 
Value 
Significant 
Pearsons 
Correlation 
Ferritin and 
Albumin 
-0.137 0.45 
Kendall's Tau_b Ferritin and 
Albumin 
0.049 0.71 
Spearman Ferritin and 
Albumin 
0.08 0.63 
TABLE NO. 4 [B]  -  GLOBULIN 
Name of the Test Correlation 
between 
Correlation 
Value 
Significant 
Pearsons 
Correlation 
Ferritin and 
Globulin 
0.317 0.08 
Kendall's Tau_b Ferritin and 
Globulin 
0.068 0.59 
 
 
Spearman Ferritin and 
Globulin 
 
0.104 0.57 
TABLE NO. 4 [C] -   ALBUMIN & GLOBULIN 
ANOVA F Ratio P Value Significant 
 101.035 O.OOO P < 0.05 
    
 
This table showed Negative correlation between Ferritin and Albumin , 
Positive Correlation between Ferritin and Globulin and were significant .  It is 
also provide by Kendall's Tau_b and spearman method by ANOVA,  F ratio 
was 101.242 which was significant [P<0.05] 
  
 
 
RELATIONSHIP BETWEEN FERRITIN AND BLOOD SUGAR 
TABLE NO. 5 [A]  -  SUGAR 
Name of the Test Correlation 
between 
Correlation 
Value 
Significant 
Pearsons 
Correlation 
Ferritin and Sugar -0.062 0.73 
Kendall's Tau_b Ferritin and Sugar -0.053 0.67 
Spearman Ferritin and Sugar -0.076 0.679 
    
TABLE NO. 5 [B] -  SUGAR 
ANOVA F Ratio P Value Significant 
 94.774 O.OOO P < 0.05 
    
 
This table evidenced that correlation between Ferritin and Sugar was 
negatively correlated by Pearson , Kendall's tau_b and spearman methods by 
ANOVA ,  
F ratio was 94.77 which showed P=0.000 [P<0.05] Hence, sugar had more 
correlation with Ferritin 
 
 
RELATIONSHIP BETWEEN FERRITIN AND BLOOD UREA AND 
SERUM CREATININE 
TABLE NO. 6 [A]  -  UREA 
Name of the Test Correlation 
between 
Correlation 
Value 
Significant 
Pearsons 
Correlation 
Ferritin and Urea 0.139 0.45 
Kendall's Tau_b Ferritin and Urea 0.071 0.58 
Spearman Ferritin and Urea 0.102 0.58 
    
TABLE NO. 6 [B]  -  CREATINE 
Name of the Test Correlation 
between 
Correlation 
Value 
Significant 
Pearsons 
Correlation 
Ferritin and 
Creatine 
0.083 0.65 
Kendall's Tau_b Ferritin and 
Creatine 
0.123 0.35 
Spearman Ferritin and 
Creatine 
0.169 0.36 
    
TABLE NO. 6 [C] -   UREA & CREATINE 
ANOVA F Ratio P Value Significant 
 
 
 100.787 O.OOO P < 0.05 
    
 
This  table proved that the correlation between Ferritin and Urea, Ferritin 
and Creatine had positively correlated and it also proved by non para metric 
correlation test by ANOVA , F ratio showed significant [P<0.05] Hence, urea 
and creatine had more effective with ferritin. 
 
  
 
 
RELATIONSHIP BETWEEN BILIRUBIN AND FERRITIN 
 
TABLE NO. 7  [A]  -  SERUM BILIRUBIN  
Name of the Test Correlation 
between 
Correlation 
Value 
Significant 
Pearsons 
Correlation 
Ferritin and 
serum bilirubin  
-0.109 0.25 
Kendall's Tau_b Ferritin and 
serum bilirubin  
-0.138 0.29 
Spearman Ferritin and 
serum bilirubin  
0.189 0.29 
    
TABLE NO. 7 [B]  -  INDIRECT BILIRUBIN 
Name of the Test Correlation 
between 
Correlation 
Value 
Significant 
Pearsons 
Correlation 
Ferritin and 
Indirect bilirubin 
-0.172 0.35 
Kendall's Tau_b Ferritin and 
Indirect bilirubin 
-0.081 0.54 
 
 
Spearman Ferritin and 
Indirect bilirubin 
-0.112 0.54 
    
TABLE NO. 7 [C] -   SERUM BILIRUBIN  & INDIRECT 
BILIRUBIN 
ANOVA F Ratio P Value Significant 
 101.348 O.OOO P < 0.05 
 
This table evidenced that correlation between SERUM BILIRUBIN  and 
Indirect showed negative correlated.  It was evidenced by Non Para Metric 
Test. By ANOVA , 
F ratio was 101.348 which was significant [P<0.05] 
  
 
 
DISCUSSION 
Beta thalassemia represents  group of recessively inherited hemoglobin 
disorders characterized by reduced synthesis of β globin chains resulting in 
severe anemia which needs repeated blood transfusion. The combination of 
transfusion and chelation therapy has dramatically improved the life 
expectancy of thalassemic children. On the other hand, frequent transfusion can 
led on to iron overload and may result in short stature , hypogonadism, diabetes 
mellitus, hypothyroidism, hypoparathyroidism, and other endocrine problems, 
cardiomyopathy, hepatic fibrosis and cirrhosis. In recent years, several authors 
have reported high incidence of these complications among patients suffering 
from thalassemia major. 
All the 32 subjects included in the study were short statured. Historically 
growth retardation is generally associated with thalassemia major children and 
is less evident in children receiving effective chelation therapy. Alternative 
causes including  endocrine dysfunction such as impaired growth hormone 
production may be considered in children who receive adequate transfusion 
and chelation therapy. 
 
 
 
Incidence of short stature in other studies 
Alizera A Shamshirsae et al
40 
39.3% 
CK Li et al 
42 
29.7% 
Present study 100% 
 
Serum ferritin levels are elevated in all children in the present study with 
median value of 3136.28 ±1761.44. in a study conducted in HongKong in 2002 
, the mean ferritin level was found to be 5140pmolL. In general the body iron 
stores have been found to correlate with serum ferritin levels. However being 
an acute phase reactant single values of serum ferritin  are not always not 
reliable. Despite serial measurements remains the simple and reliable method 
to evaluate the iron deposition and efficiency of chelation therapy. In order to 
evaluate clinical relevance, need for treatment, and timing and monitoring of 
chelation therapy, iron status should be assessed accurately. 
Splenectomy has been done for 2 out of the 32 patients in the present 
study amounting to 6.25% compared to 37% of children who had undergone 
splenectomy in a study conducted in HongKong. Splenectomy should be 
considered if annual red cell requirement exceeds 180-200ml/kg , provided 
other causes if increased consumption such as infections, hemolytic reactions 
 
 
have been ruled out. Symptoms of splenic enlargement, leucopenia, and/or 
thrombocytopenia increasing iron overload inspite of good chelation may 
necessitate splenectomy. 
 Random blood sugar estimation in the present study showed elevated 
levels in 2 out of 32 subjects i.e 6.25%. subsequent oral glucose tolerance tests 
conducted showed the presence of impaired glucose tolerance in these children.  
Present study 6.25% 
CK Li et al
42 
8.6% 
Alizera A Shamshirsae et al
40 
8.7% 
Italian working group 4.9% 
 
 In various studies the prevalence of diabetes mellitus has been reports to 
be between 6 -10%. Intensive iron chelation therapy is found to be associated 
with improvement in glucose tolerance particularly in patients with early stages 
of glucose intolerance.  
An Indian study by Jyoti Suvarna et al concluded that diabetes mellitus 
or impaired glucose tolerance was not seen in chronically transfused patients 
and insulin resistance with compensatory hyperinsulinemia sets earlier well 
 
 
before the onset of frank diabetes mellitus and correlates with the age, 
chelation therapy and indicators of iron overload. 
 Blood urea and serum creatinine is found to be normal in all subjects in 
the present study. 
Liver is affected in due to various causes including repeated transfusions 
, blood borne infections, and excessive iron deposition. Elevated liver enzymes 
were found in 18% of thalassemic individuals in  study conducted in 
HongKong. 
Subclinical hypothyroidism is defined as normal serum T4 levels with 
slightly increased TSH level. In the present study, 26.47% of children (i.e 9 out 
of 32 children) were found to have subclinical hypothyroidism. T3 and T4 
levels are found to be negatively correlating with the ferritin levels reflecting 
the effect of iron deposition in the thyroid gland. The prevalence of 
hypothyroidism is found to be between 13 -60% in patients with thalassemia 
major with varying severity in different series. 
 
 
 
 
Present study 26.47% 
Alizera A Shamshirsae et al
40 
7.7% 
CK Li et al
42 
6.9% 
Borgna – Pignatta et al41 11.6% 
 
Treatment of subclinical hypothyroidism is debatable. Close monitoring 
of the patients is necessary when treatment is considered as unnecessary. In 
overt hypothyroidism characterized by low T4 levels with signs and symptoms 
such as mental and physical letharginess, cold intolerance, weight gain, 
constipation etc, treatment with L- thyroxine is considered. Abnormal thyroid 
function may be reversible t the early stage through intensive chelation therapy. 
 None of the children among the 32 subjects were found to have 
hypocalcemia. Hypoparathyroidism manifests in about 4% of thalassemic 
patients in various studies. 
Present study 0% 
Alizera A Shamshirsae et al
40 
7.6% 
CK Li et al
42 
3.4% 
 
 
 
Cardiac iron deposition have been studied in autopsies of patients with 
transfusional hemosiderosis. Gross anatomic cardiac changes attributable to 
iron overload include dilatation of atrial and ventricular  cavities and overall 
thickening of muscle layers of heart. Moreover extent of cardiac iron 
deposition correlate  well with the occurrence of supraventricular arrhythmias. 
None of the children in the present study had cardiac complications in contrast 
to other studies. In CK Li et al study prevalance of cardiomyopathy was 15% 
with the median age of onset t 16 years. Borgna – Pignatta et al study revealed 
the presence of heart failure in 6.4% of patients, arrhythmias in 5% of 
thalassemic individuals.  
HbSAg was found to be positive in 2 children out of the 32 children. In  
CK Li et al study only 2.6% of study subjects. 
HIV is positive for 2 children in our study group. 
This study revealed the presence of mutation IVS1-5 G to C to be 71% 
and was found to be statistically significant – p<0.05(Chi –Square test). 
An extensive study done by Colah et al in 2009 showed the prevalence 
of IVS1–5(G→C) mutation in Tamilnadu and Kerala to be 56.3%.Yet another 
study by garewal and reena das et al  
46 
in 2003 declared the prevalence of this 
 
 
mutation to be 31.8% among Punjabis. Recent publication in 2011 showed 
increased prevalence of IVS1–5(G→C) in east and south India compared to 
northern, western and central India. A review article by Panja et al
47
 in 2012 
published in journal of community nutrition and health , on the contrary 
showed that codon 15 (G→A) to be common mutation in Tamilnadu. Major 
drawback in that study was that limited number of samples and studies from 
southern part of India compared to those obtained from northern states. But this 
study conducted in Madurai region, being the first of its kind among this subset 
of population showed that the most common prevailing mutation is  IVS1–
5(G→C) which is in consensus with many other studies. 
  
 
 
CONCLUSION 
 All 32 children with beta thalassemia major were  on repeated packed 
cell transfusions at an interval of  3 to 4 weeks with an average pre 
transfusion hemoglobin of 5 to 7 grams. 
 All  32 thalassemic patients were on irregular chelation therapy in spite 
of strong motivation. 
 All children were short statured and malnourished indicating the 
underlying poor nutrition acting along with the disease pathology . 
 Serum ferritin levels were invariably elevated in all patients demanding 
optimal chelation therapy. 
 Only 3 among the 32 children were found to have cardiac ailments. 
 Subclinical hypothyroidism was found in 26.45% beta thalassemic 
individuals which was found to be statistically significantly associated 
with serum ferritin levels. 
 Liver functions tests showed alterations statistically significant 
correlation with the serum ferritin levels depicting the effect of iron 
overload on the liver. 
 None of the children with beta thalassemia major had renal involvement. 
 Serum calcium levels were normal in all thalassemic subjects 
 
 
 HbSAg was positive in 2 among the 32 children 
 HIV was found to positive in 2 among the 32 children 
 All parents and 77% of the siblings were found to the thalassemic traits 
using mentzer’s index 
 The most common mutation among this subset of population was 
revealed to be IVS1–5(G→C) amounting to 71% which was found 
statistically significant. 
 None of the study subjects were found to be positive for the mutation 
cd41/42. 
 77% of the siblings were thalassemic traits who are potential targets for 
future genetic counseling. 
 
 
 
 
 
 
 
RECOMMENDATIONS 
 Need for regular transfusion must be emphasized to improve the overall 
quality and duration of life of these children 
 Rigid chelation therapy to prevent the dreadful complications of iron 
overload in thalassemic children. 
 Strict follow up and monitoring for complications and prompt 
management should be implemented. 
 Genetic counseling may be offered to siblings of these children as  a 
measure to prevent the transmission of the disease  and  thereby reduce 
the  national burden of the disease. 
 Pre implantation genetics has led to new array of hope in prevention of 
the disease in the near future. 
 
 
 
 
 
 
 
LIMITATIONS OF STUDY 
1. Total number of  patients in the study are less in number. 
2. Lack of motivation among the patients and the parents is prevalent 
among the families. 
3. Cardiac MRI, liver biopsy could not be done due to financial constraints 
4. Blood samples could not be collected at the same time. 
5. The major limitation of this study is some of the parents, siblings could 
not be sampled 
6. Genetic status for few samples could not be identified yet due to 
technical difficulties, which will be resolved. 
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PROFILE OF THALASSEMIA MAJOR CHILDREN 
NAME:  
ADDRESS: 
 
HEMATOLOGY NUMBER:       SERIAL NUMBER: 
AGE: 
SEX:                           MALE     FEMALE 
RELIGION:                        HINDU   MUSLIM  CHRISTIAN   OTHERS 
AGE AT DIAGNOSIS:            <1 YR    >1YR 
CLINICAL PRESENTATION:           YES     NO 
ANEMIA: 
HEPATOMEGALY: 
SPLENOMEGALY: 
FACIAL DYSMORPHISM: 
JAUNDICE: 
FRACTURE: 
OTHERS: 
PAST HISTORY:           MEASLES  PC   OTHERS 
ANTENATAL HISTORY:          SIGNIFICANT    NOT 
BIRTH HISTORY:                   TERM    PRETERM 
FAMILY HISTORY: 
SIBLINGS:          MALE     FEMALE 
       AFFECTED   NOT 
 
 
  
 
  
    
  
  
  
  
  
  
  
  
   
  
  
  
  
 
 
PARENTS:           CONS. M     NON CONS.M 
          
  YES     NO 
H/O HEMOGLOBINOPATHY: 
H/O OTHER ANEMIA: 
H/O BLEEDING DISORDER: 
H/O SPLENECTOMY: 
H/O CHOLECYSTECTOMY: 
IMMUNISATION HISTORY: 
HEPATITIS A: 
HEPATITIS B: 
INVESTIGATIONS: 
BL. GROUPING & TYPING:   A  B   AB   O 
     POSITIVE    NEGATIVE 
BL. HEMOGLOBIN:    <5g%  5-7g%   7-11g%  >11g% 
COOMB’S TEST:    POSITIVE    NEGATIVE 
RETICULOCYTE COUNT: 
RDW: 
PERIPHERAL SMEAR: 
 
 
LDH: 
HB ELECTROPHORESIS:   HbF   HbA2   HbA1 
  
  
  
  
  
  
  
  
    
  
    
  
 
 
 
 
   
 
 
S. IRON: 
S.FERRITIN: 
TIBC: 
BL. SUGAR: 
GTT :      0HRS   ½ HR  1HR   2HRS 
BL.UREA: 
S.CREATININE: 
S.BILIRUBIN- TOTAL: -                      DIRECT:                                INDIRECT: 
SGOT: 
SGPT: 
ALP: 
S. CALCIUM: 
S.TSH: 
S.T3: 
S.T4:    
VIRAL MARKERS:   POSITIVE    NEGATIVE 
HbSAg: 
HEPATITIS A: 
HEPATITIS C: 
ELISA FOR HIV:  
IMAGING: 
XRAY SKULL 
HAIR ON END APPEARANCE 
 
 
 
 
    
 
 
   
 
 
 
 
 
 
 
  
  
  
  
  
 
 
XRAY CHEST 
CARDIOMEGALY 
ECG: 
ECHO: 
TREATMENT DETAILS 
MODE OF TREATMENT:                          YES    NO 
PACKED CELL TRANSFUSION: 
SPLENECTOMY: 
HYDROXY UREA/ OTHERS: 
TRANSFUSION DETAILS 
TOTAL NO. OF TRANSFUSION: 
INTERVAL BETWEEN 
 EACH TRANSFUSION:  3WKS    4WKS    6WKS 
CHELATION DETAILS:  
 REGULAR CHELATION: 
 IRREGULAR CHELATION: 
 NO CHELATION: 
PHLEBOTOMY DONE:  YES    NO 
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1 alageshwari 2 f 90 18 0.6 3.5 3 37 19 130 7.8 4.7 3.1 normal study 2611.6 1.13 7.5 1.24 2nd ramnad
2 alex pandian 7 m 86 15 0.5 1.5 1 35 35 130 6.8 4 2.8 normal study 1632.9 1.64 11.6 2.71 ncm tirunelveli
3 arun 5 m 121 19 0.6 0.9 0.3 29 28 71 5.2 3.1 2.1 normal study 1797 1.49 11.3 2.08 3rd viruthungr
4 azhahar 10 m 83 19 0.8 1 0.4 63 73 263 7.1 3.6 3.5 normal study 2546 1.09 10.3 6.96 3rd mdu
5 deepak kumar 3 m 96 26 0.7 4.5 4 29 38 122 6 4 2 normal study 1994 1.06 7.6 2.41 3rd mdu
6 deepan 5 m 94 31 0.8 1 0.6 100 86 354 5 3 2 normal study 854 1.2 9.2 2.36 ncm dindugal
7 dharanishri 5 f 84 22 0.8 0.8 0.4 44 44 123 6.8 4 2.8 normal study 2654 1.3 8.6 1.92 3rd mdu
8 dharmar 11 m 81 20 0.6 0.9 0.5 115 80 227 7.7 3.2 4.5 normal study 8792 1.19 8.2 1.86 2nd mdu
9 hari 5 m 130 16 1 0.7 0.2 65 25 165 6.3 3.3 3 normal study 5246.8 1.43 8.3 2.85 ncm theni
10 jagadeshwari 8 f 88 22 0.8 1 0.5 29 37 130 6.1 4 2.1 normal study 3870.5 0.83 10.2 8.65 ncm virudhungr
11 karthik 9 m 132 18 1.1 1.2 0.4 56 40 45 7 3.7 3.3 dilated coronary sinus; small ASD os 2758.8 0.96 10 0.92 3rd mdu
12 maheshraj 5 m 102 20 0.9 1 0.4 60 42 90 6.4 3.8 2.6 normal study 2880.8 1.4 7.8 1.4 3rd mdu
13 mathimalar 5 f 100 27 0.9 1.5 1 292 167 282 7 3.4 3.6 normal study 7135.3 1.2 7.2 2.38 3rd theni
14 mohamed arif 2 m 90 22 0.7 1 0.2 0.8 32 100 7.1 3.9 3.2 normal study 943 1.2 8 1.4 3rd mdu
15 mohana 1 f 60 16 0.5 1.2 0.4 392 224 635 7 4.2 2.8 normal study 3200 1.4 9 1.32 3rd mdu
16 muthupandi 8 m 84 26 0.6 0.9 0.4 54 46 243 5.6 3.2 2.4 normal study 5921.7 1.6 10.4 1.2 3rd mdu
17 naveen kumar 3 m 72 29 1.3 1 0.5 48 18 147 5.8 3.2 2.6 normal study 2228.8 1.39 11.5 3.65 ncm mdu
18 nebura 6 f 170 14 1.1 1 0.4 62 44 38 7.4 4 3.4 normal study 1209 1.4 9.8 2.4 3rd mdu
19 pandimeena 5 f 81 19 0.8 0.9 0.4 77 88 190 7.4 3.4 4 normal study 1752.7 1.15 9.8 3.01 2nd mdu
20 praveen 8 m 294 25 1.1 1 0.4 67 80 92 7 3.5 3.5 bicuspid aortic valve with fused raphe, AR mild 3205 1.2 8.4 2.32 3rd mdu
21 rajalakshmi 11 f 69 78 2 2 1.5 40 39 251 6.9 4 2.6 normal study 4338 1.02 9.9 4.07 ncm madurai
22 rajeshwari 12 f 84 20 0.6 1 0.5 48 38 112 6.8 4 2.6 normal study 2904 1.15 7.8 2.1 3rd mdu
23 ramana 9 m 80 24 0.8 1.2 0.4 48 41 103 7 4 3 normal study 4656.7 1.3 8.2 1.92 3rd mdu
24 ramya 9 f 87 23 0.9 1 0.5 47 44 111 5 3 2 normal study 2188.9 1.49 8.4 2.51 2nd virudhungr
25 riyaz 11 m 103 16 0.9 0.7 0.3 38 37 75 6.6 4.3 2.3 normal study 4501.4 0.9 9 6.16 3rd mdu
26 rohini 9 f 83 16 0.7 1 0.4 24 57 159 6.4 3.4 3 normal study 4068 1.46 9.1 1.86 ncm dindugal
27 sabarish 2 1/2 m 102 23 0.9 0.9 0.4 62 45 238 5.9 3.4 2.5 normal study 2580.9 1.99 10.9 5.27 3rd theni
28 saravanakumar 5 m 92 20 0.8 1.1 0.5 44 41 102 6.9 4 2.9 normal study 3421 1.4 9.2 1.4 3rd theni
29 selvaraj 9 m 80 20 0.6 5 4 40 35 48 6.4 3.8 2.6 normal study 1640.5 1.37 9.9 0.35 3rd mdu
30 subashri 4 f 90 18 0.6 3.5 3 37 19 130 7.8 4.7 3.1 normal study 2611.6 1.13 7.5 1.24 2nd ramnad
31 yogashri 5 f 100 14 0.6 2 1 720 50 580 7 3.2 3.8 normal study 2324.2 1.37 11.1 7.23 3rd mdu
32 yuvan raja 3 m 84 21 0.6 1.2 0.4 45 35 124 7 3.8 3.2 slightly dilated LV, MR grade 1 1892 1.3 9.2 1.3 3rd theni
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